



PHARMACEUTICAL 2022











PHARMACEUTICAL 2022

XOMA Corp Rank 16 of 475



The relative strengths and weaknesses of XOMA Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 247% points. The greatest weakness of XOMA Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 8.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 507% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	96,973
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,967
Liabilities, Non-Current	34
Other Assets	69,576
Other Compr. Net Income	0
Other Expenses	552
Other Liabilities	11,685
Other Net Income	-1,179
Property and Equipment	13
Research and Development	171
Revenues	38,160
Selling, General and Administrative Expense	20,460

Output Variable	Value in 1000 USD
Assets	166,562
Liabilities	24,686
Expenses	21,183
Stockholders Equity	141,876
Net Income	15,798
Comprehensive Net Income	15,798
Economic Capital Ratio	230%

